Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1975 1
1976 4
1977 2
1978 2
1979 1
1990 1
1995 2
1998 1
2002 1
2003 3
2004 2
2005 5
2006 2
2007 8
2008 5
2009 8
2010 3
2011 10
2012 10
2013 5
2014 7
2015 13
2016 11
2017 17
2018 23
2019 27
2020 15
2021 21
2022 16
2023 20
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: T.-Jardi
Page 1
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Davies M, et al. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. Lancet. 2021. PMID: 33667417 Clinical Trial.
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lincoff AM, Marso SP, Fries TM, Plutzky J, Ryan DH; SELECT Study Group. Lingvay I, et al. Obesity (Silver Spring). 2023 Jan;31(1):111-122. doi: 10.1002/oby.23621. Epub 2022 Dec 10. Obesity (Silver Spring). 2023. PMID: 36502289 Free PMC article. Clinical Trial.
Mitochondrial Ion Channels.
Szabo I, Szewczyk A. Szabo I, et al. Annu Rev Biophys. 2023 May 9;52:229-254. doi: 10.1146/annurev-biophys-092622-094853. Annu Rev Biophys. 2023. PMID: 37159294 Free article. Review.
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Reis S, et al. Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2. Cochrane Database Syst Rev. 2022. PMID: 36126225 Free PMC article. Updated. Review.
A revolution in obesity treatment.
Lingvay I, Agarwal S. Lingvay I, et al. Nat Med. 2023 Oct;29(10):2406-2408. doi: 10.1038/s41591-023-02538-7. Nat Med. 2023. PMID: 37735562 No abstract available.
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ. Lingvay I, et al. Lancet Diabetes Endocrinol. 2019 Nov;7(11):834-844. doi: 10.1016/S2213-8587(19)30311-0. Epub 2019 Sep 17. Lancet Diabetes Endocrinol. 2019. PMID: 31540867 Clinical Trial.
226 results